BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
View original at globenewswire.comBioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Pumitamig ROSETTA Lung-02 data marks the third global dataset to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapy, following SCLC and TNBC datasets
60% confidenceBioNTech's growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies
60% confidenceGotistobart results add to the growing body of evidence supporting its potential as a chemotherapy-free treatment option, complementing recently announced data in second and later line squamous NSCLC
60% confidenceBioNTech is advancing novel-novel combination approaches including ADC-based regimens to unlock the full synergistic potential of its pipeline
60% confidenceThe ROSETTA Lung-02 Phase 2 results inform the ongoing pivotal Phase 3 part evaluating pumitamig plus chemotherapy versus pembrolizumab plus chemotherapy
60% confidenceGotistobart PRESERVE-004 Phase 2 data showed durable anti-tumor activity and clinically meaningful overall survival outcomes in platinum-resistant ovarian cancer with manageable safety profile
60% confidenceAchieving more for patients with cancer through translating science into innovative therapies is BioNTech's unwavering ambition
60% confidenceBioNTech has more than 25 Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials
60% confidenceBioNTech's oncology strategy is building a diversified portfolio of complementary modalities delivering differentiated therapeutic profiles across tumor types with high unmet medical need
60% confidenceBioNTech is focused on accelerating key strategic programs as monotherapies and combinations with standard of care to deliver its first wave of oncology innovations to patients
60% confidence
Data points we hold from this source
| BioNTech SE · parameter count | 6 asco_2026_presentations |